Naftopidil 75mg for Improving Clearance of Urinary Stones

• Status: Unknown status
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate Efficacy and Safety of oral intake of Naftopidil 75mg once daily for the improving clearance of ureteral or renal stones.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Collaborator: Dong-A ST Co., Ltd.
• Treatments: Naftopidil

Criteria

Inclusion Criteria:

• Radio-opaque (identifiable in KUB) ureter or kidney calculi

• size criteria is from 5mm to 15mm

Exclusion Criteria:

• Symptomatic acute urinary tract infection during the run-in period

• severe hydronephrosis

• 2 or more urinary stones

• Radiolucent (non-visible in KUB) stone

• recent intervention for the urinary stone within 6 month

• Patients who have ureteral stent

• over 2.0 mg/dl of serum creatinine level

• severe hepatic dysfunction

• orthostatic hypotension

• current usage of alpha-adrenergic blocker or calcium channel blocker

• Pregnant or nursing women

• Age under 15 year

• severe or uncontrolled medical conditions